Valneva Touts Additional Positive Heterologous Booster Data From COVID-19 Vaccine Study – Yahoo Finance

Valneva SE (NASDAQ: VALNreported further heterologous booster data from an exploratory, small clinical study for its inactivated COVID-19 vaccine, VLA2001.
The data show that a booster dose of VLA2001 was well tolerated in previously vaccinated participants with either Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) or Moderna Inc (NASDAQ: MRNA) shots.
The data confirm the favorable safety profile of VLA2001 seen across all studies, including in homologous or heterologous booster settings.
However, in this study, an additional booster dose of VLA2001 elicited only a marginally increased neutralizing antibody response, Valneva added.
Also see: France Health Body Advises Unfavorable Opinion Regarding Valneva’s COVID-19 Vaccine.
The company previously reported positive heterologous booster results following primary vaccination with AstraZeneca Plc’s (NASDAQ: AZN) vaccine – in August 2022 and positive homologous booster results at the end of December 2021.
Valneva is currently seeking regulatory approval for VLA2001 as a homologous and heterologous booster in AstraZeneca – primed individuals who may support the company deploying its inventory in international markets.
Price Action: VALN shares closed at $12.72 on Friday.
Photo Via Wikimedia Commons
See more from Benzinga
Valneva Concludes FDA Regulatory Submission For One-Shot Chikungunya Vaccine
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2023 Benzinga does not provide investment advice. All rights reserved.
Related Quotes
The European Union said Tuesday it has offered China help to deal with its COVID-19 crisis, including the donation of vaccines, as the bloc seeks to coordinate how authorities should check incoming passengers from China for any new variants.
With a price-to-earnings (or "P/E") ratio of 5.9x Moderna, Inc. ( NASDAQ:MRNA ) may be sending very bullish signals at…
Photo Illustration by The Daily Beast / GettyImmune therapies have rewritten the game when it comes to cancer treatment, earning the “fifth pillar” label next to more tried and true treatments like radiation therapy, surgery, and chemotherapy. And no immunotherapy has garnered quite the same excitement as CAR T-cell therapy, first approved in 2017 by the Food and Drug Administration to treat a form of acute lymphoblastic leukemia. At the time, then-FDA Commissioner Scott Gottlieb called the appr
The European Union has offered free COVID-19 vaccines to China, the EU executive said on Tuesday, as infections there surged following Beijing's relaxation of its "zero-COVID" policies. China has not responded to the offer yet, a spokesperson for the European Commission told journalists at a regular briefing. "In view of the COVID situation in China, (Health) Commissioner Stella Kyriakides has reached out to her Chinese counterparts to offer EU solidarity and support," he said.
Three New York City police officers were injured after being attacked with a machete near New Year’s Eve celebrations in Times Square, authorities said.
Novak Djokovic said Tuesday the reception he had received in Australia was more than he could wish for and the good vibes would reflect in his tennis as he targets a 22nd Grand Slam title this month.
Alexis Mac Allister insists he is happy to stay at Brighton after helping Argentina win the World Cup.
Actor Jeremy Renner is out of surgery on Monday after he was injured while plowing snow on Sunday, according to his publicist. "We can confirm that Jeremy has suffered blunt chest trauma and orthopedic injuries and has undergone surgery today," his publicist said in a statement Monday evening. "He has returned from surgery and remains in the intensive care unit in critical but stable condition."
“The Great Resignation, Quiet Quitting, and record levels of job openings proved that the war for talent is over, and talent has won ,” said chief marketing officer at Greenhouse.
(Bloomberg) — NATO Secretary General Jens Stoltenberg said allies are pushing to strengthen the alliance’s target of spending 2% of output on defense, with the aim of reaching an agreement by July.Most Read from BloombergElon Musk Becomes First Person Ever to Lose $200 BillionChina’s Foreign Minister Says ‘Deeply Impressed’ With AmericansUkraine Latest: Strike Kills 63 Russian Troops in Occupied TownUkraine warned that Russia may launch more attacks over the Orthodox Christmas holiday later thi
Eli Lilly's (NYSE: LLY) biosimilar drug known as Rezvoglar was given the green light by the U.S. Food and Drug Administration (FDA) to be marketed as an interchangeable to Sanofi's (NASDAQ: SNY) Lantus long-acting insulin. This follows the FDA's approval of Rezvoglar as a biosimilar last December. What prompted the FDA to make Rezvoglar the second interchangeable biosimilar to Sanofi's Lantus behind Viatris' (NASDAQ: VTRS) Semglee?
Roche Holding (OTC: RHHBY) and Gilead Sciences (NASDAQ: GILD) both saw increased sales during the pandemic, due in part to their COVID-19 products. For Gilead, it was its COVD-19 antiviral, Veklury, and for Roche, its revenue was boosted mostly by coronavirus tests. Gilead's shares have glittered in 2022, with the stock up more than 16%, while Roche's have fallen more than 23% so far this year.
Having multiple prescriptions is difficult enough to keep track of, let alone ones with complicated names. Hill Street Studios/Stone via Getty ImagesAt some point in your life, you’ll likely find yourself with a prescription from your doctor to fill. While it’s important to keep track of all the medications you’re taking, that can be hard to do when the names of so many of these drugs are difficult to pronounce and even harder to remember. In my role as a pharmacist, I’ve helped countless patien
Stocks of Take-Two Interactive Software, Micron Technology, and Warner Bros. Discovery all tanked. Some on Wall Street think 2023 will be a lot better.
Tesla stock had a rocky 2022, and Tesla investors hoped that fourth-quarter EV deliveries would help get 2023 started with a bang. It looks like they’ll be disappointed, as the actual numbers fell short of expectations, sending Tesla stock lower in premarket trading Tuesday. On Monday, Tesla (ticker: TSLA) reported fourth-quarter deliveries of 405,278.
The Securities Commission of The Bahamas says it is holding these assets pending transfer to clients and creditors.
ADM (ADM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Take a look at these three top-ranked, best-performing and well-managed mutual funds if you're looking to maximize your retirement portfolio returns.
Will the market continue to consolidate in 2023?
(Bloomberg) — Swedish oat milk maker Oatly Group AB will transfer leases and production capacity at two US facilities to Canadian manufacturer Ya YA Foods Corp. in a co-packing agreement that is part of its shift to an “asset-light” supply-chain strategy, the companies announced in a joint statement on Tuesday. Most Read from BloombergElon Musk Becomes First Person Ever to Lose $200 BillionChina’s Foreign Minister Says ‘Deeply Impressed’ With AmericansUkraine Latest: Strike Kills 63 Russian Tro